Kathmere Capital Management’s GSK GSK Stock Holding History

Kathmere Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$570K	Buy	10,882 +1,602	+17%	+$84.7K	0.03%	371
2026 Q1	$512K	Buy	9,280 +1,637	+21%	+$88.7K	0.03%	353
2025 Q4	$375K	Buy	7,643 +379	+5%	+$17.7K	0.03%	372
2025 Q3	$314K	Buy	7,264 +685	+10%	+$26.8K	0.02%	386
2025 Q2	$253K	Sell	6,579 -884	-12%	-$33.8K	0.02%	401
2025 Q1	$289K	Buy	+7,463	New	+$273K	0.02%	336
2024 Q4	–	Sell	-5,053	Closed	-$207K	–	420
2024 Q3	$207K	Buy	+5,053	New	+$207K	0.02%	361
2021 Q1	–	Sell	-640	Closed	-$29K	–	251
2020 Q4	$29K	Buy	+640	New	+$29.4K	0.01%	267

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Kathmere Capital Management's GSK Position: Q2 2026 in Review

Kathmere Capital Management increased its GSK (GSK) stake by 17% in Q2 2026, buying an estimated $84.7K and bringing the position to 10,882 shares worth $570K. The position accounts for 0.03% of the portfolio, ranked #371.

Kathmere Capital Management first reported a position in GSK in Q4 2020 and has held it in 8 quarters since. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Kathmere Capital Management held 10,882 shares of GSK worth $570K as of Q2 2026.
Kathmere Capital Management bought 1,602 GSK shares in Q2 2026, an estimated $84.7K.
GSK made up 0.03% of Kathmere Capital Management's portfolio in Q2 2026, its #371 holding.
Kathmere Capital Management first reported a position in GSK in Q4 2020 and has held it in 8 quarters since.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.